Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269421 | 0.91 | NPSR1 (0.52) | MAOBMAPTPOLBNPSR1TAS1R3 | |
| SCHEMBL13236835 | 0.88 | CYP1A1 (0.52) | MAOBMAPTKDM4EKDRNPSR1 | |
| SCHEMBL11296725 | 0.85 | ALDH1A1 (0.54) | MAPTPOLBKDM4ENPSR1KMT2A | |
| SCHEMBL11891940 | 0.85 | ALDH1A1 (0.54) | MAPTPOLBKDM4ENPSR1KMT2A | |
| SCHEMBL11296722 | 0.85 | ALDH1A1 (0.54) | MAPTPOLBKDM4ENPSR1KMT2A | |
| SCHEMBL8937390 | 0.84 | MAOB (0.56) | MAOBMAPTPOLBKDM4EKDR | |
| SCHEMBL8937385 | 0.84 | MAOB (0.56) | MAOBMAPTPOLBKDM4EKDR | |
| SCHEMBL8937392 | 0.84 | MAOB (0.56) | MAOBMAPTPOLBKDM4EKDR | |
| SCHEMBL4389147 | 0.83 | CES2 (0.54) | MAOBMAPTPOLBNPSR1KMT2A | |
| SCHEMBL4389151 | 0.83 | CES2 (0.54) | MAOBMAPTPOLBNPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-7750048-B2 | GPR40 agonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-06 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176912-A1 | GPR40 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176912-A1 | GPR40 AGONISTS | GPR119, GPR65, GPR55 | MAOB 3722/4885MAPT 3979/4885POLB 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.